Florentin S.
- Country
- Sweden
- Department
- Department of Hematology, Cancercenter
Research Overview
- Evaluation of Intermittent Ibrutinib Administration in Patients with Chronic Lymphocytic Leukemia
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
- Phase 3 Multicenter Randomized Trial of Venetoclax, Obinutuzumab, and Pirtobrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Data & Insights
Has run more than one trial at 73 of 197 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular expertise in novel therapeutic approaches for previously untreated patients.
- Treatment-naive CLL/SLL management
- Targeted therapy combinations
- Novel therapeutic strategies
Their research explores innovative treatment modalities and combination therapies for hematologic malignancies.
Therapeutic Innovation
The investigator focuses on developing fixed-duration treatment protocols and MRD-guided therapy approaches using cutting-edge targeted agents.
- Personalized treatment duration
- Novel drug combinations
- Treatment optimization strategies
Their work encompasses innovative approaches to therapy duration and timing in blood cancers.
Clinical Applications
The investigator evaluates targeted therapeutic agents including venetoclax, obinutuzumab, pirtobrutinib, and ibrutinib in various combinations and schedules.
- Combination therapy assessment
- Treatment duration optimization
- Drug efficacy evaluation
Their research aims to establish optimal treatment protocols for blood cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.